Switch from conventional selegiline to xilopar™ allows dose reduction of levodopa and dopamine agonists

Authors
Category Primary study
JournalNeurologie und Rehabilitation
Year 2001
This article has no abstract
Epistemonikos ID: b89f6865ab7f7d46074c40a3607f065e5e43a56e
First added on: Feb 03, 2025